A drug safety evaluation of mogamulizumab for the treatment of cutaneous T-Cell lymphoma. Issue 9 (2nd September 2019)

• Record Type: Journal Article
• Authors: Afifi, Salma; Mohamed, Sara; Zhao, Jennifer; Foss, Francine
• Is Part Of: Expert opinion on drug safety. Volume 18:Issue 9(2019)
• Page Start: 769
• Page End: 776
• Publication Date: 2019-09-02
• Subjects: Cutaneous T-cell lymphoma -- CTCL -- mycosis fungoides -- Sezary syndrome -- CCR4 -- mogamulizumab; Drugs -- Side effects -- Periodicals; Drugs -- Toxicology -- Periodicals; Chemotherapy -- Periodicals; 615.704
• DOI: 10.1080/14740338.2019.1643837
• Languages: English
• ISSNs: 1474-0338

Abstract

ABSTRACT: Introduction : Cutaneous T-cell lymphomas (CTCL) are rare non-Hodgkin lymphomas of skin-homing T-cells that initially or mainly manifest cutaneously. Treatment of CTCL is challenging given the disease states' varying presentation and prognosis. Systemic treatment options often lack comparative evidence and have relatively low response rates and short duration of response. The recent Food and Drug Administration (FDA) approval of mogamulizumab in adult patients with relapsed or refractory (R/R) CTCL after at least one prior line of therapy provided a new treatment option to patients with advanced disease. Areas covered : The authors discuss basic information about CTCL and mogamulizumab's mechanism of action. Then, the authors discuss the agent's efficacy. Finally, the authors evaluate the safety of mogamulizumab in comparison to other agents available in CTCL. Expert opinion : Mogamulizumab has been shown to be an effective and well tolerated therapy for patients with relapsed and refractory MF/SS with excellent activity in the circulating component of the disease.